Phase 4 N=40 Effects of Omega-3 Fatty Acids on the Human Gene Expression
Hyperlipidemia · Healthy
Primary: Gene Expression Changes — 841; 1041; 1639; 628 number of regulated genes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=27 Gene Expression, Meditative Movement, and Emotional Distress (GME)
Cognitive Impairment
Primary: Perceived Cognitive Impairments (CogPCI) — 17.3 units on a scale — p=.01
N/A N=21 Gene Expression Study Between Two Dermal Injectables Hydroxylapatite Semi-permanent Filler
Gene Expression
Primary: Gene Expression — 1; 1; 1; 4 Significantly upregulated genes
Phase 4 N=20 Tumor Gene Expression in Women With Ovarian Cancer
Ovarian Cancer
Primary: Increase in SGK1 mRNA Expression Level — 1.5; 6.1 fold change
Phase 4 N=9 Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® Photodynamic Therapy (PDT)
Actinic Keratosis
Primary: Percent Change From Baseline in Lesion Count at Week 18 — 95.5 percent change
N/A N=10 Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy Volunteers
Hepatitis B
Primary: Number of Differentially Expressed Genes at p < 0.05 (Without Multiple Testing Correction). — 138; 138; 102; 81 number of genes at p<0.05
Phase 1 N=18 Pharmacogenomics of the Variability in the In Vivo Response to Glucocorticoids
Glucocorticoids Toxicity · Glucose Intolerance
Primary: White Blood Cell Counts — 5.26; 6.99 x10^3 cells/mL
Phase 4 N=12 Gene Regulation by Thiazolidinediones
Inflammatory Bowel Disease
Primary: PDK4 mRNA — .776; 1.30 copies/nL — p=.01
N/A N=12 Carbohydrate Availability and microRNA Expression
Glycogen Depletion
Primary: Fold Change in microRNA Expression From Baseline — 0.73; 1.36 fold change
N/A N=1,398 Genomics Used to Improve DEpression Decisions
Major Depressive Disorder (MDD)
Primary: Percent Change in the 17-item Hamilton Depression (HAM-D17) Score From Baseline to 8 Weeks — -24.39; -27.23 percentage of change — p=0.1070
Phase 4 N=34 Pharmacogenomics of Antiplatelet Response
Atherosclerosis
Primary: Differential Gene Expression — 77.1 FPKM for HBG1 Gene — p=<0.000005
N/A N=20 Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma
Eosinophilic Asthma
Primary: Differentially Expressed Genes — 149 differentially expressed gene
Phase 2 N=20 Study in Healthy Adults to Evaluate Gene Activation After Vaccination With GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342
Tuberculosis
Primary: Concentration of Specific Interferon Gamma (IFN-γ) Antibodies Secreted in Serum Samples — 6279.7 fg/mL
N/A N=400 The Genetics of Evoked Responses to Niacin and Endotoxemia: The GENE Study
Healthy Volunteers
Primary: Baseline and Peak TNF-alpha Values as Categorized by Race and Gender — 1.08; 43.48; 1.03; 37.28 pg/ml
Phase 2 N=35 Single Dose of pGM169/GL67A in CF Patients
Cystic Fibrosis
Primary: Body Maximum Temperature — 38.6; 38.0; 37.4 celsius — p=0.0002
N/A N=59 Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer
Ductal Breast Carcinoma in Situ · Lobular Breast Carcinoma in Situ · Stage II Breast Cancer
Primary: The Proportion of Patients With RS 11-25 Who Refused the Assigned Treatment — 0.15 proportion of participants
N/A N=548 North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2
Epilepsy; Seizure · Neuromuscular Diseases · Brain Malformation
Primary: Initial Patient Pediatric Quality of Life (Peds QL) Score — 64.37; 65.83; 60.04; 63.39 score on a scale
Phase 2 N=237 S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer
Bladder Cancer
Primary: Assessment of Whether the Treatment-specific COXEN Score is Prognostic of pT0 Rate — 8; 10; 20; 17 Participants — p=0.1
Phase 3 N=44 Plant Cell Expressed Recombinant Human Glucocerebrosidase Extension Trial
Gaucher Disease
Primary: Spleen Volume — 2324.0; 2120.0; 778.0; 1707.7 mL
Phase 4 N=135 Investigation of Genetic Predictors of the Response to Selective Serotonin Re-uptake Inhibitors (SSRI) Treatment
Major Depression
Primary: Montgomery-Asberg's Depression Rating Scale — 9.2 score on a scale
N/A N=50 Tacrolimus Adjustment by NFAT-related Gene Expression in Lung Allograft Recipients.
Transplantation, Lung
Primary: Association of Percentage of Mean Residual Expression (MRE%) of NFAT-related Cytokine Expression and Acute Cellular Rejection — 39.5; 41.7 percentage of mean residual…
N/A N=82 Cytokine Expression During Radiation for Breast Cancer
Breast Cancer
Primary: Number of Proteins Expressed Differently in Response to Receiving Radiation Therapy — 31 Proteins
N/A N=251 PCP Use of a Gene Expression Test (Corus CAD or ASGES) in Coronary Artery Disease Diagnosis
Chest Pain · Cardiovascular Diseases · Angina Pectoris
Primary: Change in Clinicians' Treatment Decision After Age/Sex/Gene Expression Score — 38; 1; 1; 0 number of subjects — p=<0.001
N/A N=58 Molecular Mechanisms of Exercise Benefits to Insulin Resistant People
Insulin Resistance · Obesity
Primary: Change in Muscle Strength — 0.37; -0.2 Ratio
N/A N=685 An Open Label Study of Clinical Utility and Patient Outcomes of the Genecept Assay
Treatment Resistant Depression · Generalized Anxiety Disorder
Primary: Change From Baseline in Clinical Global Impressions Improvement (CGI-I) Scale at 3 Months — 545; 386 Participants
N/A N=30 Expression of Longevity Genes in Response to Extended Fasting
Cardiovascular Disease
Primary: Change From Baseline in Participant Glucose When Fasting and Fed — 83.3; -8.0; 5.9 mg/dL
Phase 4 N=31 Centocor Microarray Study of Patients
Rheumatoid Arthritis · Psoriatic Arthritis · Psoriasis
Primary: Baseline (Wk 0) Disease Activity Score (DAS28) — 4.54; 6.03 Score
Phase 2 N=71 Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma
Multiple Myeloma
Primary: Progression-free Survival (PFS) After Initiation of Pomalidomide Therapy — 13 percentage of participants
Phase 2 N=5 Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer
Adenocarcinoma of the Prostate · Stage II Prostate Cancer · Stage III Prostate Cancer
Primary: Efficacy as Assessed by Number of Patients With Changes Across Transcript Profiles by Microarray Analysis in Prostate Cancer Specimens, Specifically Those With Complete…
Phase 2 N=13 Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate Cancer
Prostate Cancer
Primary: Relative Expression of U19 Gene in Tumor From Prostate Gland During First Off-cycle. — 0.24; 0.28 Relative expression